...
首页> 外文期刊>Annals of surgical oncology >Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon alpha 2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer
【24h】

Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon alpha 2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer

机译:1b期临床试验以评估组织对第二剂量的膀胱内重组腺病毒干扰素α2b的反应,该治疗针对非肌肉浸润性膀胱癌的卡介苗-芽孢杆菌(BCG)疗法失败而在Syn3中制定

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A phase 1b trial was conducted to evaluate the duration of interferon-alpha (IFN alpha) production after intravesical administration of recombinant adenovirus-mediated interferon alpha 2b (Ad-IFN) formulated with the excipient Syn3. The primary aim was to determine whether a second instillation 3 days after initial treatment produced prolonged urinary IFN production.
机译:进行了1b期临床试验,以评估膀胱内施用由赋形剂Syn3配制的重组腺病毒介导的干扰素α2b(Ad-IFN)后,干扰素α(IFN alpha)产生的持续时间。主要目的是确定初始治疗后3天再滴注是否会延长尿中IFN的产生。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号